All News

Sundar Jagannath, MBBS, highlights pharmacists’ expanding role in managing linvoseltamab’s immunologic profile, supporting adverse event response, and advancing multiple myeloma care.

Eileen Peng, PharmD, discusses how her team has restructured pharmacy services to support outpatient administration of CAR T-cell and bispecific therapies—emphasizing multidisciplinary collaboration, early toxicity management, real-world data integration, and pharmacist-led care transitions to ensure safety and continuity across care settings.

Two pharmacy leaders at UNC Health share how their distinct yet complementary leadership journeys and skill sets are driving innovation in clinical practice, education, and team development across the health system.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the collaborative culture, research opportunities, and leadership pathways that define oncology pharmacy practice at Atrium Health Wake Forest Baptist, while emphasizing the importance of advocacy and visibility for the profession.

Maximizing pharmacists’ impact on medication safety requires removing barriers to intervention and empowering proactive clinical roles.

The FDA approves aceclidine ophthalmic solution 1.44%, the first aceclidine eye drop for presbyopia, offering a new solution for millions struggling with near vision loss.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

The approval builds upon concizumab’s previous December 2024 clearance and allows for treatment in patients with hemophilia A or B, both with or without inhibitors.

The authors note that the findings can have significant public health implications given the widespread water chlorination and increased chronic kidney disease (CKD) burden.

Patients should be supported by a multidisciplinary team, frequent evaluations, and behavioral therapy for optimal care.

Lawmakers across the country can learn from examples in states like Arkansas and Texas.

Ivermectin shows promise in reducing malaria cases, enhancing vector control, and highlighting pharmacists' vital roles in public health strategies.

Kirk Knowlton, MD, discusses findings from the V-INCEPTION trial evaluating inclisiran for low-density lipoprotein cholesterol (LDL-C) management after myocardial infarction, highlighting its real-world effectiveness, tolerability, and potential for integration into pharmacist-led lipid care pathways.

Sanofi's SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.

New research reveals that GLP-1 receptor agonists like semaglutide may significantly reduce stroke impacts and improve recovery outcomes.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

By targeting aldosterone in a 2-dose regimen, baxdrostat effectively lowers mean seated systolic blood pressure in patients with difficult-to-treat hypertension.

Pirtobrutinib shows promising results in a head-to-head trial against ibrutinib for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

A recent study reveals Mvasi's comparable safety profile to Avastin for retinal diseases, highlighting the need for on-label biosimilars in ophthalmology.

Decentralized pharmacists play a critical role in reducing medication errors by collaborating in real time with physicians and nurses to enhance patient safety across care settings.

Both vaccine and non-vaccine serotypes were identified as being resistant to critical antimicrobial treatments for pneumococcal disease.

Hormonal contraceptives present a nuanced risk-benefit profile, slightly increasing breast and cervical cancer risk while significantly reducing ovarian and endometrial cancer rates.

Understanding the regulatory landscape can maximize pharmacists' roles while ensuring legal compliance

Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.

Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.